A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy
There are many mechanisms of resistance, chemoresistance of HeLa cells to anti-cancer agents seems to be autophagy-mediated. While using very effective anti-cancers such as Doxorubicin and cisplatin, cells overcome the cytotoxicity of these drugs through promotion of what so-called cytoprotective au...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-12-01
|
| Series: | Saudi Pharmaceutical Journal |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S131901641930132X |
| _version_ | 1818544678235013120 |
|---|---|
| author | Moureq Rashed Alotaibi Homood Moqbel As Sobeai Faten Abdullah Alaqil Mashal Almutairi Khalid Alhazzani Adam A.A. Sulaiman Anvarhusein A. Isab Nasser Hadal Alotaibi |
| author_facet | Moureq Rashed Alotaibi Homood Moqbel As Sobeai Faten Abdullah Alaqil Mashal Almutairi Khalid Alhazzani Adam A.A. Sulaiman Anvarhusein A. Isab Nasser Hadal Alotaibi |
| author_sort | Moureq Rashed Alotaibi |
| collection | DOAJ |
| description | There are many mechanisms of resistance, chemoresistance of HeLa cells to anti-cancer agents seems to be autophagy-mediated. While using very effective anti-cancers such as Doxorubicin and cisplatin, cells overcome the cytotoxicity of these drugs through promotion of what so-called cytoprotective autophagy. Here in this study, we sought to introduce a novel platinum-based compound PBC-II that possesses anti-cancer activity. Our data showed that PBC-II is able to induce apoptosis at relatively low concentrations, with no detectable reactive oxygen species (ROS). However, further experiments demonstrated that exposure of HeLa cells to PBC-II did not promote autophagy; rather, it resulted in accumulation of p62 and decrease in LC3-II levels. Autophagy was then promoted in HeLa cells pharmacologically by Doxorubicin and genetically by siRNA IL-10. In order to confirm promotion of autophagy in our model, we performed acridine orange staining to assess for autophagy under microscope as well as via flow cytometry. We then measured protein level of autophagy markers p62 and LC3 by western blot. Our data indicated that PBC-II interferes with therapy-induced autophagy. We also determined PI3K activity while co-incubation of PBC-II with autophagy inducers. It was clear that PI3K activation decreased when PBC-II was co-administered with autophagy inducers. Collectively, PBC-II exerts unique anti-proliferative effects associated with inhibition of autophagy, which indicates that PBC-II is potentially a promising agent to be used in resistant ovarian tumors. Keywords: Ovarian, Autophagy, Doxorubicin, IL-10, Platinum, HeLa |
| first_indexed | 2024-12-11T22:51:34Z |
| format | Article |
| id | doaj.art-3d3651b4f80b4684b31bb189a5e64d2c |
| institution | Directory Open Access Journal |
| issn | 1319-0164 |
| language | English |
| last_indexed | 2024-12-11T22:51:34Z |
| publishDate | 2019-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Saudi Pharmaceutical Journal |
| spelling | doaj.art-3d3651b4f80b4684b31bb189a5e64d2c2022-12-22T00:47:25ZengElsevierSaudi Pharmaceutical Journal1319-01642019-12-0127812031209A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagyMoureq Rashed Alotaibi0Homood Moqbel As Sobeai1Faten Abdullah Alaqil2Mashal Almutairi3Khalid Alhazzani4Adam A.A. Sulaiman5Anvarhusein A. Isab6Nasser Hadal Alotaibi7Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; Corresponding author at: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud, University, Post Box 2457, Riyadh 11451, Saudi Arabia.Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi ArabiaDeanship of Scientific Research, King Saud University, Riyadh, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi ArabiaLab Technical Support Office (LTSO), King Fahd University of Petroleum and Minerals, Dhahran 31261, Saudi ArabiaDepartment of Chemistry, King Fahd University of Petroleum and Minerals, Dhahran 31261, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakakah 72341, Saudi ArabiaThere are many mechanisms of resistance, chemoresistance of HeLa cells to anti-cancer agents seems to be autophagy-mediated. While using very effective anti-cancers such as Doxorubicin and cisplatin, cells overcome the cytotoxicity of these drugs through promotion of what so-called cytoprotective autophagy. Here in this study, we sought to introduce a novel platinum-based compound PBC-II that possesses anti-cancer activity. Our data showed that PBC-II is able to induce apoptosis at relatively low concentrations, with no detectable reactive oxygen species (ROS). However, further experiments demonstrated that exposure of HeLa cells to PBC-II did not promote autophagy; rather, it resulted in accumulation of p62 and decrease in LC3-II levels. Autophagy was then promoted in HeLa cells pharmacologically by Doxorubicin and genetically by siRNA IL-10. In order to confirm promotion of autophagy in our model, we performed acridine orange staining to assess for autophagy under microscope as well as via flow cytometry. We then measured protein level of autophagy markers p62 and LC3 by western blot. Our data indicated that PBC-II interferes with therapy-induced autophagy. We also determined PI3K activity while co-incubation of PBC-II with autophagy inducers. It was clear that PI3K activation decreased when PBC-II was co-administered with autophagy inducers. Collectively, PBC-II exerts unique anti-proliferative effects associated with inhibition of autophagy, which indicates that PBC-II is potentially a promising agent to be used in resistant ovarian tumors. Keywords: Ovarian, Autophagy, Doxorubicin, IL-10, Platinum, HeLahttp://www.sciencedirect.com/science/article/pii/S131901641930132X |
| spellingShingle | Moureq Rashed Alotaibi Homood Moqbel As Sobeai Faten Abdullah Alaqil Mashal Almutairi Khalid Alhazzani Adam A.A. Sulaiman Anvarhusein A. Isab Nasser Hadal Alotaibi A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy Saudi Pharmaceutical Journal |
| title | A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy |
| title_full | A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy |
| title_fullStr | A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy |
| title_full_unstemmed | A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy |
| title_short | A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy |
| title_sort | newly synthesized platinum based compound pbc ii increases chemosensitivity of hela ovarian cancer cells via inhibition of autophagy |
| url | http://www.sciencedirect.com/science/article/pii/S131901641930132X |
| work_keys_str_mv | AT moureqrashedalotaibi anewlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT homoodmoqbelassobeai anewlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT fatenabdullahalaqil anewlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT mashalalmutairi anewlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT khalidalhazzani anewlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT adamaasulaiman anewlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT anvarhuseinaisab anewlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT nasserhadalalotaibi anewlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT moureqrashedalotaibi newlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT homoodmoqbelassobeai newlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT fatenabdullahalaqil newlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT mashalalmutairi newlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT khalidalhazzani newlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT adamaasulaiman newlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT anvarhuseinaisab newlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy AT nasserhadalalotaibi newlysynthesizedplatinumbasedcompoundpbciiincreaseschemosensitivityofhelaovariancancercellsviainhibitionofautophagy |